{"id":"W2042093910","doi":"10.1016/j.ygyno.2005.09.032","title":"A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study","year":2005,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Regimen; Tirapazamine; Ovarian cancer; Cisplatin; Gynecologic oncology; Internal medicine; Chemotherapy; Oncology; Progressive disease; Chemotherapy regimen; Surgery; Adverse effect; Phases of clinical research; Ovarian carcinoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002260264,0.0004657867,0.001893609,0.0003451976,0.0001737656,0.000007527418,0.0002237711,0.0004423007,0.001488698],"category_scores_gemma":[0.000450024,0.0002797496,0.0002408871,0.0006380212,0.0003337129,0.00008263558,0.00009107762,0.0003200441,0.00001094911],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00846713,"about_ca_system_score_gemma":0.002525703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000654157,"about_ca_topic_score_gemma":0.01743437,"domain_scores_codex":[0.9948056,0.00176733,0.001386631,0.0007813117,0.0006649568,0.0005941388],"domain_scores_gemma":[0.9951916,0.00277486,0.000924534,0.0005769736,0.0004011577,0.0001308611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.006877163,0.1103675,0.01197055,0.00005525704,0.0007460172,0.0006266746,0.02182391,0.0004278129,0.0005250624,0.000122494,0.0004220777,0.8460355],"study_design_scores_gemma":[0.119234,0.4397858,0.3960981,0.00009163832,0.003677349,0.0002111535,0.009933181,0.004651232,0.0005412772,0.00009489368,0.02528358,0.0003977547],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809694,0.001326811,0.000008601806,0.004706752,0.0006037942,0.007165845,0.0001179515,0.00003435918,0.005066542],"genre_scores_gemma":[0.9916736,0.001324179,0.001546439,0.0006894227,0.0003217191,0.004157902,0.0001583441,0.00002460925,0.0001037376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8456377,"threshold_uncertainty_score":0.9999655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09526104529368758,"score_gpt":0.4222465381856592,"score_spread":0.3269854928919717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}